New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 4, 2013
13:21 EDTMNOVMedicNova price target lowered to $6 from $10.50 at Ladenburg
Ladenburg reduced its target on MedicNova after the company indicated that the FDA would require the company to show through a Phase III trial that its asthma treatment reduces hospitalizations. However, the firm continues to be upbeat on the stock and maintains a Buy rating.
News For MNOV From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 27, 2015
08:12 EDTMNOVMediciNova announces FDA approval of second Phase 2 protocol for MN-001 in NASH
MediciNova announced that FDA has approved a second protocol for a clinical trial evaluating MN-001 for a NASH indication. This study targets NASH patients with hypertriglyceridemia to evaluate the ability of MN-001 to improve cardiovascular risk by assessing cholesterol-efflux capacity and serum triglyceride levels as well as reduction of percent fat in the liver, as assessed by MRI.
July 21, 2015
08:08 EDTMNOVMediciNova announces update on development plans for MN-001 in IPF
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use